Brandon Folkes
Stock Analyst at Rodman & Renshaw
(2.02)
# 1,919
Out of 4,479 analysts
32
Total ratings
27.5%
Success rate
-0.02%
Average return
Main Sectors:
20 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MNKD MannKind | Initiates: Buy | $8 | $5.03 | +59.05% | 1 | Jun 13, 2024 | |
| TRVI Trevi Therapeutics | Initiates: Buy | $7 | $2.68 | +161.19% | 1 | Jun 13, 2024 | |
| HRTX Heron Therapeutics | Initiates: Buy | $7 | $2.74 | +155.47% | 1 | Jun 13, 2024 | |
| RANI Rani Therapeutics Holdings | Initiates: Buy | $10 | $3.87 | +158.40% | 2 | Jun 13, 2024 | |
| SCLX Scilex Holding Company | Initiates: Buy | $13 | $1.93 | +573.58% | 1 | Jun 13, 2024 | |
| OMER Omeros | Downgrades: Neutral | n/a | $3.85 | - | 1 | Nov 10, 2023 | |
| SMTI Sanara MedTech | Reiterates: Overweight | $59 | $27.70 | +113.00% | 4 | Sep 26, 2023 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $180 | $105.09 | +71.28% | 2 | Aug 22, 2023 | |
| VERU Veru Inc. | Maintains: Overweight | $30 → $22 | $0.95 | +2,207.05% | 2 | Dec 5, 2022 | |
| DERM Journey Medical | Initiates: Overweight | $9 | $5.24 | +71.76% | 1 | Feb 25, 2022 | |
| ALKS Alkermes | Upgrades: Overweight | $28 → $32 | $24.19 | +32.29% | 1 | Jan 27, 2022 | |
| RDHL RedHill Biopharma | Initiates: Overweight | n/a | $0.36 | - | 1 | Aug 31, 2021 | |
| COLL Collegium Pharmaceutical | Downgrades: Neutral | n/a | $32.04 | - | 3 | Aug 6, 2021 | |
| PYPD PolyPid | Initiates: Overweight | n/a | $4.00 | - | 1 | Jul 30, 2021 | |
| TRVN Trevena | Initiates: Overweight | n/a | $0.21 | - | 1 | Aug 28, 2020 | |
| EBS Emergent BioSolutions | Maintains: Overweight | n/a | $7.49 | - | 3 | Jul 17, 2020 | |
| ANIP ANI Pharmaceuticals | Downgrades: Neutral | n/a | $62.64 | - | 2 | May 7, 2020 | |
| OPTN OptiNose | Reiterates: Overweight | n/a | $1.04 | - | 1 | Mar 5, 2020 | |
| EGRX Eagle Pharmaceuticals | Maintains: Neutral | n/a | $5.23 | - | 2 | Mar 2, 2020 | |
| BHVN Biohaven Pharmaceutical Holding Company | Maintains: Overweight | n/a | $34.17 | - | 1 | Jul 12, 2018 |
MannKind
Jun 13, 2024
Initiates: Buy
Price Target: $8
Current: $5.03
Upside: +59.05%
Trevi Therapeutics
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $2.68
Upside: +161.19%
Heron Therapeutics
Jun 13, 2024
Initiates: Buy
Price Target: $7
Current: $2.74
Upside: +155.47%
Rani Therapeutics Holdings
Jun 13, 2024
Initiates: Buy
Price Target: $10
Current: $3.87
Upside: +158.40%
Scilex Holding Company
Jun 13, 2024
Initiates: Buy
Price Target: $13
Current: $1.93
Upside: +573.58%
Omeros
Nov 10, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.85
Upside: -
Sanara MedTech
Sep 26, 2023
Reiterates: Overweight
Price Target: $59
Current: $27.70
Upside: +113.00%
Jazz Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $180
Current: $105.09
Upside: +71.28%
Veru Inc.
Dec 5, 2022
Maintains: Overweight
Price Target: $30 → $22
Current: $0.95
Upside: +2,207.05%
Journey Medical
Feb 25, 2022
Initiates: Overweight
Price Target: $9
Current: $5.24
Upside: +71.76%
Alkermes
Jan 27, 2022
Upgrades: Overweight
Price Target: $28 → $32
Current: $24.19
Upside: +32.29%
RedHill Biopharma
Aug 31, 2021
Initiates: Overweight
Price Target: n/a
Current: $0.36
Upside: -
Collegium Pharmaceutical
Aug 6, 2021
Downgrades: Neutral
Price Target: n/a
Current: $32.04
Upside: -
PolyPid
Jul 30, 2021
Initiates: Overweight
Price Target: n/a
Current: $4.00
Upside: -
Trevena
Aug 28, 2020
Initiates: Overweight
Price Target: n/a
Current: $0.21
Upside: -
Emergent BioSolutions
Jul 17, 2020
Maintains: Overweight
Price Target: n/a
Current: $7.49
Upside: -
ANI Pharmaceuticals
May 7, 2020
Downgrades: Neutral
Price Target: n/a
Current: $62.64
Upside: -
OptiNose
Mar 5, 2020
Reiterates: Overweight
Price Target: n/a
Current: $1.04
Upside: -
Eagle Pharmaceuticals
Mar 2, 2020
Maintains: Neutral
Price Target: n/a
Current: $5.23
Upside: -
Biohaven Pharmaceutical Holding Company
Jul 12, 2018
Maintains: Overweight
Price Target: n/a
Current: $34.17
Upside: -